IIIA期黑色素瘤前哨淋巴结中孤立肿瘤细胞与IB期相似的有利预后相关
研究比较IIIA期(ic)与IIIA期黑色素瘤的生存结局,发现IIIA期(ic)预后接近IB期。图宾根队列10年无复发生存率IIIA期(ic)84% vs IIIA期49%,DeCOG队列88% vs 35%。作者认为IIIA期(ic)推荐辅助治疗需充分讨论。
要点
- IIIA期(ic)黑色素瘤10年RFS在图宾根队列为84%,DeCOG队列为88%。
- IIIA期(ic)预后与IB期相似,辅助治疗推荐需充分讨论。
- AJCC第8版将含任何肿瘤细胞的前哨淋巴结定义为阳性,导致薄黑色素瘤伴孤立肿瘤细胞被归为IIIA期。
核心结论
- IIIA期(ic)黑色素瘤表现出与IB期相似的预后。
- 在IIIA期(ic)推荐辅助治疗需要充分的讨论。
研究设计与样本
- 发现队列来自图宾根大学医院皮肤科,包括237例患者;确认队列来自DeCOG试验,包括143例患者。
- 图宾根队列包括95例IIIA期(ic)和142例IIIA期患者;DeCOG试验包括39例IIIA期(ic)和104例IIIA期患者。
- 主要终点为无复发生存(RFS)和远处无转移生存(DMFS);次要终点为黑色素瘤特异性生存(MSS)。
主要发现
- 图宾根队列10年RFS率:IIIA期(ic)84%(95%CI 75-94) vs IIIA期49%(95%CI 39-59),p < 0.001。
- 图宾根队列10年DMFS率:IIIA期(ic)89%(95%CI 81-97) vs IIIA期56%(95%CI 45-67),p < 0.001。
- DeCOG队列10年RFS率:IIIA期(ic)88%(95%CI 78-99) vs IIIA期35%(95%CI 7-62),p = 0.009。
- DeCOG队列10年DMFS率:IIIA期(ic)88%(95%CI 77-99) vs IIIA期60%(95%CI 39-80),p = 0.061。
临床怎么用
- 作者认为,在IIIA期(ic)黑色素瘤中推荐辅助治疗需要充分的讨论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Joint Committee on Cancer 8th edition (AJCC v8) defines sentinel lymph nodes (SLN) containing any tumor cells as positive SLN. Consequently, even thin melanomas with isolated tumor cells (ic) in SLN are classified as stage IIIA, making them candidates for adjuvant therapy. OBJECTIVES AND ENDPOINTS: We aimed to evaluate survival outcomes of melanoma stage IIIA (ic) and compare them with stage IIIA with lymph node (LN) metastases > 0.1 mm. Primary endpoints were relapse-free survival (RFS) and distant metastases-free survival (DMFS). Secondary endpoint was melanoma specific survival (MSS). RESULTS: The discovery cohort from the Department of Dermatology, University Hospital Tuebingen, included 237 patients; confirmation cohort included 143 patients from the DeCOG trial. The Tuebingen cohort included 95 patients with stage IIIA (ic) and 142 patients with stage IIIA. The DeCOG trial included 39 patients with stage IIIA (ic) and 104 patients with stage IIIA. In the Tuebingen cohort, 10-year RFS rates for stage IIIA (ic) and IIIA were 84% (95% CI 75-94) and 49% (95% CI 39-59), respectively (p < 0.001). 10-year DMFS rates for stage IIIA (ic) and IIIA were 89% (95% CI 81-97) and 56% (95% CI 45-67), respectively; (p < 0.001). In the DeCOG cohort, 10-year RFS for stage IIIA (ic) and stage IIIA were 88% (95% CI 78-99) and 35% (95% CI 7-62), respectively; (p = 0.009). 10-year DMFS for stage IIIA (ic) and IIIA was 88% (95% CI 77-99) and 60% (95% CI 39-80), respectively (p = 0.061). CONCLUSION: Stage IIIA (ic) melanoma exhibits a prognosis similar to stage IB. Recommendation of adjuvant therapy in Stage IIIA (ic) warrants thorough discussion.
引用
- Amaral T, Nanz L, Stadler R, et al. Isolated melanoma cells in sentinel lymph node in stage IIIA melanoma correlate with a favorable prognosis similar to stage IB. Eur J Cancer. 2024. PMID: 38368742. doi:10.1016/j.ejca.2024.113912
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。